Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Lorna Benson
St. Paul, Minn.

U-led group suggests ways to fast-track Ebola vaccines

Ebola vaccine
Doctor Francis Kateh volunteers to receive a trial vaccine against Ebola, February 3, 2015. The first large-scale trials of two Ebola vaccines began in Liberia on February 2.
Zoom Dosso | AFP | Getty Images

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

An international team of vaccine experts has published a roadmap for fast-tracking the development of safe and effective Ebola vaccines for use in Africa. The group was convened by the University of Minnesota and the Wellcome Trust, a London-based charitable foundation.

The fast-track document is intended to compliment the vaccine development work already underway by manufacturers, regulators and public health agencies, including the World Health Organization. However, the so-called "Team B" group that created the fast-track document operates independently from those frontline vaccine efforts.

"We think that we are able to bring a slightly different perspective that is complimentary to what's going on," said Michael Osterholm who co-chaired the 26-member group.

Osterholm, director of the U of M's Center for Infectious Disease Research and Policy, says Team Bs are supposed to challenge assumptions and bring fresh eyes to a difficult task.

"So if there's something being missed, it can be readily picked up," said Osterholm.

There are formidable challenges to accelerating the search for Ebola vaccines from figuring out the right vaccine dose to making sure that the product is safe and can be produced in sufficient quantities.

The Team B report suggests dozens of ways regulators could hasten the development of Ebola vaccines in Africa.

Among the group's recommendations:

• Focus on monovalent vaccines in the near term that are designed to protect against a single strain of Ebola
• Evaluate all promising vaccines in clinical trials
• Consider frontline workers as a priority group
• Promote West African leadership
• Match strategies to each country
• Ensure transparency
• Consider stockpiling vaccines for future use

Ebola has been around since the mid-1970s but vaccine development efforts have been slow, partly because previous outbreaks have been small. That changed with the massive outbreak in West Africa last year.

Several Ebola vaccine candidates are already being tested in humans. But the declining incidence of Ebola disease in West Africa may make the vaccine quest more challenging.

"If you don't have a large number of cases it's going to take much longer before you can actually determine: Does this vaccine work or not?" said Osterholm.